Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.
BMJ Open
; 12(12): e063650, 2022 12 23.
Article
in En
| MEDLINE
| ID: mdl-36564123
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Arthritis, Psoriatic
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
BMJ Open
Year:
2022
Type:
Article
Affiliation country:
United States